

231. The method of claim 229, further comprising isolating said gene product prior to said screening in (c). --

Remarks

No new matter has been added by the foregoing amendment to the specification, which has been made solely to provide the application number for the priority application filed on March 8, 1999, which number was not available at the time of filing of the present application.

The foregoing amendments to the claims are fully supported in the specification as originally filed. Specifically, support for new claims 58-227 may be found in the specification at pages 6-17, at pages 38-44, at pages 50-53, at pages 57-61, at pages 68-118, and throughout the Examples; and support for new claims 228-231 may be found in the specification at pages 7, 12, 32, 35, 67, 69, and 72-73. Accordingly, the foregoing amendments to the claims do not add new matter; their entry is therefore respectfully requested. Upon entry of the foregoing amendments, claims 1-7, 10-15, 20-36, and 58-231 are pending in the present application, with claims 1, 5, 6, 10, 30, 58-62, 83, 85-87, 98, 109, 110, 113, 116, 118, 124, 126, 127, 133-135, 138, 145, 149, 151, 154, 157, 189, 196, 197, 205, 208, 218, 223, 225, 228 and 229 being the independent claims.

Applicants believe that the present application is now in condition for examination. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of the foregoing amendments, and entry of the same into the present application, are respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Agent for Applicants
Registration No. 42,473

Date: July 22, 1999

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

P91-98.wpd